Volume 1.36 | Sep 24

Prostate Cell News 1.36, September 24, 2010.
In this issue: Science News  |   Current Publications  |   Industry News  |   Policy News  |   Events Subscribe   |  Unsubscribe

TOP STORY

Transcriptional Coactivators p300 and CBP Stimulate Estrogen Receptor-Beta Signaling and Regulate Cellular Events in Prostate Cancer 
Steroid receptor coactivators p300 and CBP are highly expressed in advanced prostate cancer. They potentiate activation of androgen receptor by androgens and anti-androgens. In the present study, researchers addressed the question of whether these coactivators enhance activity of estrogen receptor-beta, which is variably expressed in prostate cancers. [Prostate]

ALDEFLUORCSC_645x110



SCIENCE NEWS

Molecule 968 Binds Glutaminase and Starves Cancer Cells, say Cornell Biologists
A molecule – simply called 968 – can starve cancer cells and the tumors they produce, says new research. [Press release from Cornell University discussing online prepublication in Cancer Cell]

Robot-Assisted Radical Prostatectomy Offers Effective 5-Year Cancer Control
Prostate cancer patients treated with robot-assisted radical prostatectomy can expect low rates of biochemical recurrence after 5 years, study findings showed. [Press release from MedWire News discussing online prepublication in European Urology]

Watch Procedure Now  
Optimized Enzymes and Protocols for
Prostate Tissue Dissociation

by STEMCELL Technologies
 
 
CLICK HERE TO LEARN MORE STEMCELL Technologies Inc
 



CURRENT PUBLICATIONS  (Ranked by Impact Factor of the Journal)

LABORATORY RESEARCH

Targeting Mitochondrial Glutaminase Activity Inhibits Oncogenic Transformation
Researchers described a small molecule inhibitor that blocks oncogenic transformation induced by various Rho GTPases in fibroblasts, and the growth of human breast cancer and B lymphoma cells, without affecting normal cells. [Cancer Cell]

A New Paradigm for Aptamer Therapeutic AS1411 Action: Uptake by Macropinocytosis and Its Stimulation by a Nucleolin-Dependent Mechanism
AS1411 is a first-in-class anticancer agent, currently in Phase II clinical trials. The data suggest a new model for AS1411 action, as well as a new role for nucleolin in stimulating macropinocytosis, a process with potential applications in drug delivery. [Cancer Res]

DLC1 Negatively Regulates Angiogenesis in a Paracrine Fashion
In this study, researchers silenced DLC1 in non-malignant prostate epithelial cells to explore its tumor suppression functions. [Cancer Res]

Chromatin Loading of E2F-MLL Complex by Cancer-Associated Coregulator ANCCA via Reading a Specific Histone Mark
The results suggest that ANCCA acts as a pioneer factor in E2F-dependent gene activation and that a novel mechanism involving ANCCA bromodomain may contribute to cancer cell proliferation. [Mol Cell Biol]

Research Resource: Estrogen-Driven Prolactin-Mediated Gene-Expression Networks in Hormone-Induced Prostatic Intraepithelial Neoplasia
In this study, researchers delineate the specific action(s) of E2 and prolactin in early prostate carcinogenesis by an integrated approach combining global transcription profiling, gene ontology, and gene-network mapping. [Mol Endocrinol]

Expression Pattern of Receptor Activator of NF(Kappa)B (RANK) in a Series of Primary Solid Tumors and Related Bone Metastases
Researchers retrospectively examined RANK ligand expression by immunohistochemistry in 74 bone metastases tissues from solid tumors, mostly breast, colorectal, renal, lung and prostate cancer. [J Cell Physiol ]

Changes in Cortical Cytoskeletal and Extracellular Matrix Gene Expression in Prostate Cancer are Related to Oncogenic ERG Deregulation
Specific changes in the cortical cytoskeleton were observed during prostate cancer progression. They parallel changes in the expression of extracellular matrix components and all together appear to be associated with oncogenic ERG overexpression. Researchers hypothesize that these alterations may contribute to the increased invasivity conferred to prostate cancer cells by ERG deregulation. [BMC Cancer]

CLINICAL RESEARCH

Castration-Dependent Pharmacokinetics of Docetaxel in Patients With Prostate Cancer
The objective of this study was to assess whether the low incidence of severe neutropenia in castrated men with prostate cancer treated with docetaxel was the result of changes in systemic clearance. [J Clin Oncol]

Biochemical Recurrence Following Robot-Assisted Radical Prostatectomy: Analysis of 1384 Patients with a Median 5-Year Follow-Up
In a contemporary cohort of patients with localized prostate cancer, robot-assisted radical prostatectomy confered effective 5-year biochemical control. [Eur Urol]

Single-Nucleotide Polymorphisms in p53 Pathway and Aggressiveness of Prostate Cancer in a Caucasian Population
In this study, researchers analyzed the association of single-nucleotide polymorphisms in p53, Mdm2, Mdm4 and Hausp genes with prostate cancer clinicopathologic variables in a large hospital-based Caucasian prostate cancer cohort (N = 4073). [ Clin Cancer Res]

A Phase II Study of Estramustine, Docetaxel, and Bevacizumab in Men with Castrate-Resistant Prostate Cancer
The combination of docetaxel, estramustine, and bevacizumab was tolerable but complicated by toxicity. Although the endpoint of progression-free survival did not meet the desired level, encouraging antitumor activity and overall survival were observed. [Cancer]



INDUSTRY NEWS

Genmab and Seattle Genetics Enter into Antibody-Drug Conjugate Research Collaboration
Genmab A/S and Seattle Genetics, Inc. announced that the companies have entered into an antibody-drug conjugate research collaboration agreement. [Seattle Genetics, Inc. Press Release]

Unichem Laboratories receives CEP for Alfuzosin Hydrochloride
Unichem Laboratories Limited has been granted Certificate of suitability to European Pharmacopeia (CEP) by European Directorate for the Quality of Medicines and Healthcare (EDQM) for Alfuzosin Hydrochloride. [Unichem Laboratories Limited Press Release]

Scripps Research Team Wins $5.1 Million to Develop DNA Sequencing Technology
Scripps Research Institute Professor Reza Ghadiri has been awarded a four-year, $5.1 million grant as part of a National Institutes of Health initiative to spur the development of the next generation of DNA sequencing technologies, which could enable biomedical researchers and health care workers to routinely sequence a person’s DNA. [Scripps Research Institute Press Release]

Online System Helps Manage Prostate Cancer Treatment
A web-based software system that could help health professionals to manage the treatment of prostate cancer has been developed in the United Kingdom. [The Engineer]



POLICY NEWS

NHGRI Funds Development of Third Generation DNA Sequencing Technologies
More than $18 million in grants to spur the development of a third generation of DNA sequencing technologies was announced by the National Human Genome Research Institute. [National Institutes of Health, United States]

Innovative Emerging Molecular Analysis Technologies (SBIR R43/R44) (RFA-CA-10-013) [National Institutes of Health, United States]

Prospective Grant of Exclusive License: The Development of Immunotoxins/Targeted Toxins for the Treatment of Human Cancer (FR Doc. 2010-22844) [National Institutes of Health, United States]

National Human Genome Research Institute; Notice of Closed Meeting (FR Doc. 2010-23027) [National Institutes of Health, United States]

National Cancer Institute; Notice of Closed Meeting (FR Doc. 2010-23144) [National Institutes of Health, United States]

Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-23143) [National Institutes of Health, United States]

Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-23275) [National Institutes of Health, United States]


EVENTS (Listed by Date)

International Society for Cellular Therapy 2nd Annual Symposium on Stem Cell Translation: Best Practices & Regulatory Considerations
September 27-28, 2010
San Francisco, United States

35th European Society for Medical Oncology (ESMO) Congress
October 8-12, 2010
Milan, Italy

American Association for Cancer Research (AACR) Translational Cancer Research for Basic Scientists
October 17-22, 2010
Boston, United States

NEW  6th Modern Drug Discovery & Development Summit (M3D)
October 20-22, 2010
San Francisco, United States

NEW  American Institute for Cancer Research (AICR) 2010 Annual Research Conference
October 21-22, 2010
Washington, DC, United States

NEW  MENA Oncology Conference
October 22-23, 2010
Cairo, Egypt

Frontiers in Tumour Progression
October 24-27, 2010
Madrid, Spain

NEW  Select Biosciences 3rd Annual Molecular Diagnostics World Congress
October 28-29, 2010
San Diego, United States

NEW  UAE Cancer Congress 2010
October 28-30, 2010
Dubai, United Arab Emirates

NEW  6th National Cancer Research Institute (NCRI) Conference
November 7-10, 2010
Liverpool, United Kingdom

9th Annual AACR International Conference: Frontiers in Cancer Prevention Research
November 7-10, 2010
Philadelphia, United States

NEW  22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
November 16-19, 2010
Berlin, Germany

Cancer Pharmacogenetics: Personalizing Medicine
November 22-24, 2010
Madrid, Spain

The 10th Annual Meeting of the Society Of Urologic Oncology (SUO) – 10th Annual Winter Meeting
December 3-5, 2010
Bethesda, United States

NEW  33rd Annual San Antonio Breast Cancer Symposium
December 8-12, 2010
San Antonio, United States

NEW  American Association for Cancer Research (AACR) Stem Cells, Development, and Cancer
March 3-6, 2011
Vancouver, Canada

IMPaCT: Innovative Minds in Prostate Cancer Today 2011
March 9-12, 2011
Orlando, United States

NEW  The 6th International Conference on Oncolytic Viruses as Cancer Therapeutics
March 16-19, 2011
Las Vegas, United States

American Association for Cancer Research (AACR) 102nd Annual Meeting 2011
April 2-6, 2011
Orlando, United States

NEW  International Society for Stem Cell Research (ISSCR) 9th Annual Meeting
June 15-18, 2011
Toronto, Canada

American Association for Cancer Research (AACR) Cancer Research Imaging Camp
June 19-24, 2011
St. Louis, United States

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.


JOB OPPORTUNITIES


Cell Therapy Technologist (Opexa Therapeutics)

Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Prostate Cell News.
Visit here to post your career opportunities.


Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.


Learn more about Prostate Cell News: Archives  |   Events  |   Subscribe  |   Contact Us